Ademi LLP probes Esperion's $1.1B deal with ARCHIMED over possible fiduciary breaches.

Ademi LLP is investigating Esperion's recent $1.1 billion transaction with ARCHIMED for potential breaches of fiduciary duty and other legal violations. Esperion shareholders will receive $3.16 per share plus contingent rights to milestone payments based on future sales. Concerns include substantial benefits to insiders and restrictive terms limiting competing bids. The investigation focuses on whether Esperion's board acted in shareholders' best interests.